Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Amarantus Bioscience Holdi AMBS
Posted On: 09/20/2014 12:08:39 AM
Post# of 30066
Avatar
Posted By: redspeed
Re: zoomboom #6973
Notice this is plural "undisclosed therapeutic indications".

The news release is all about retinal repair which narrows down the list of orphans a bit. One can speculate why Amarantus has kept this hush-hush where RP has been know for a long-time. If this leads to treatment of AMD, that could be huge.

San Francisco, CA, Geneva, SWITZERLAND and Novato, CA – August 11, 2014 - Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, announced it has entered into a Research Collaboration with the Buck Institute for Research on Aging for the development of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) in undisclosed therapeutic indications . MANF is a targeted therapeutic which addresses the underlying programmed cell death (apoptosis) associated with a wide range of devastating human disorders including orphan indications such as Retinitis Pigmentosa.

http://www.buckinstitute.org/buck-news/amaran...laboration













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site